Author

Jiankang Zhang

Herbert Irving Comprehensive Cancer CenterORCID 0000-0003-0365-7238Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Jiankang Zhang1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Alison Marie TayloriD· 1 shared Anjali SaqiiD· 1 shared Brian S. HenickiD· 1 shared Chloe A PaolucciiD· 1 shared Fereshteh ZandkarimiiD· 1 shared Joan Josep CastellanoiD· 1 shared Laura ByroniD· 1 shared Marco A. MarraiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alison Marie TaylorORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintMay 8, 2026

Aneuploidy sensitizes cells to SREBP-pathway inhibition in squamous cell carcinoma

Nadja Zhakula-Kostadinova, Sejal Jain, Zeinab Amini‐Farsani…·Alison Marie Taylor

This study identifies that 3q-gain aneuploidy in squamous cell carcinomas creates a vulnerability to SREBP-pathway inhibition, offering a target for lipid-targeted therapies.

DOI 10.64898/2026.05.04.722276

humanwhole-genome sequencing

𝕏 PostBluesky